Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 7/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072608 | 0.90 | KLK5 (0.39) | ACSS2TRPV1ALDH1A1HSD17B10MTNR1A | |
| SCHEMBL7070421 | 0.89 | ACSS2 (0.39) | ACSS2TRPV1KDM4EALDH1A1HPGD | |
| SCHEMBL7071922 | 0.88 | NOD1 (0.37) | ACSS2TRPV1KDM4EALDH1A1HPGD | |
| SCHEMBL7069778 | 0.85 | NOD1 (0.40) | ACSS2HPGDNOD1F9 | |
| SCHEMBL7068356 | 0.84 | ACSS2 (0.37) | ACSS2TRPV1KDM4EALDH1A1HPGD | |
| SCHEMBL7071907 | 0.84 | NOD1 (0.38) | ACSS2TRPV1MTNR1ANOD1CYP2C19 | |
| SCHEMBL7067770 | 0.80 | NOD1 (0.37) | TRPV1ALDH1A1NOD1F9TP53 | |
| SCHEMBL7068332 | 0.80 | F2 (0.40) | TRPV1ALDH1A1HSD17B10MTNR1ANOD1 | |
| SCHEMBL7128797 | 0.79 | TRPV1 (0.34) | ACSS2TRPV1MTNR1ANOD1CYP2C19 | |
| SCHEMBL7072014 | 0.79 | ACSS2 (0.39) | ACSS2TRPV1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | ACSS2 609/4885TRPV1 823/4885KDM4E 3525/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | ACSS2 746/4885TRPV1 954/4885KDM4E 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.